Implications from Research on Lymphoma and Immune System Diseases in Nigeria
DOI:
https://doi.org/10.64229/zpkfwy71Keywords:
Lymphoma, Immune System Disorders, Single-Cell Sequencing, Hiv, Tumor Microenvironment, Precision Medicine, Hematological MalignanciesAbstract
Nigeria, with its unique genetic diversity and high burden of infectious diseases, presents a distinctive landscape for studying hematological malignancies, particularly lymphomas. The interplay between immune system disorders and lymphomagenesis in this population remains poorly understood, necessitating the application of advanced single-cell technologies to unravel the complex mechanisms involved. This comprehensive review explores the current understanding of lymphoma epidemiology and molecular subtypes in Nigeria, examines the intricate relationships between various immune disorders and lymphoma development, and discusses how single-cell sequencing (SCS) technologies can transform diagnostic precision, prognostic assessment, and therapeutic strategies. We highlight the significant role of HIV-mediated immune dysregulation, iatrogenic immunosuppression, and chronic infections in shaping the lymphoma spectrum in Nigeria. The implementation of SCS approaches offers unprecedented opportunities to dissect tumor heterogeneity, characterize tumor microenvironment composition, and identify novel therapeutic targets tailored to the Nigerian population. Despite challenges related to infrastructure and technical expertise, strategic integration of single-cell technologies into Nigeria's research landscape holds promise for advancing precision oncology and improving clinical outcomes for lymphoma patients. This article provides a roadmap for future research directions and collaborative opportunities that could significantly enhance our understanding of lymphomagenesis in this unique population.
References
[1]Zinzani, P. L., et al. (2023). ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma. Journal of Clinical Oncology, *41*(?), ?. https://doi.org/10.1200/JCO.23.00775
[2]Adams, B., Lazarchick, J., & Medina, A. M. (2010). Iatrogenic immunodeficiency–associated lymphoproliferative disease of the Hodgkin lymphoma–like variant in a patient treated with mycophenolate mofetil for autoimmune hepatitis. American Journal of Hematology, 85(8), 627–629. https://doi.org/10.1002/ajh.21753
[3]Akarolo-Anthony, S.N., Ogundiran, T.O. & Adebamowo, C.A. Emerging breast cancer epidemic: evidence from Africa. Breast Cancer Res 12 (Suppl 4), S8 (2010). https://doi.org/10.1186/bcr2737
[4]Alizadeh, A., Eisen, M., Davis, R. et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403, 503–511 (2000). https://doi.org/10.1038/35000501
[5]Basso, K., Dalla-Favera, R. Germinal centres and B cell lymphomagenesis. Nat Rev Immunol 15, 172–184 (2015). https://doi.org/10.1038/nri3814
[6]Bray, F., Ferlay, J., Soerjomataram, I., et al. (2018). Global cancer statistics 2018: GLOBOCAN estimates. CA: A Cancer Journal for Clinicians, 68(6), 394–424. https://doi.org/10.3322/caac.21492
[7]Chinen, J., & Shearer, W. T. (2010). Secondary immunodeficiencies, including HIV infection. Journal of Allergy and Clinical Immunology, 125(2), S195–S203. https://doi.org/10.1016/j.jaci.2009.08.040
[8]Cibulskis, K., Lawrence, M., Carter, S. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol 31, 213–219 (2013). https://doi.org/10.1038/nbt.2514
[9]Evans DG, Woodward ER, Bajalica-Lagercrantz S, Oliveira C, Frebourg T. Germline TP53 Testing in Breast Cancers: Why, When and How? Cancers. 2020; 12(12):3762. https://doi.org/10.3390/cancers12123762
[10]Singh-Moodley, A., Ismail, H., & Perovic, O. (2020). Molecular diagnostics in South Africa and challenges in the establishment of a molecular laboratory in developing countries. The Journal of Infection in Developing Countries, 14(03), 236–243. https://doi.org/10.3855/jidc.11779
[11]Lenz, G., & Staudt, L. M. (2010). Aggressive lymphomas. New England Journal of Medicine, 362(15), 1417–1429. https://doi.org/10.1056/NEJMra0807082
[12]Molyneux, E. M., Rochford, R., Griffin, B., et al. (2012). Burkitt's lymphoma. Lancet, 379(9822), 1234–1244. https://doi.org/10.1016/S0140-6736(11)61177-X
[13]Alderton, G. Modifying MYC expression. Nat Rev Cancer 11, 627 (2011). https://doi.org/10.1038/nrc3132
[14]Mohammedi, L., Doula, F. D., Mesli, F., & Senhadji, R. (2019). Cyclin D1 overexpression in Algerian breast cancer women: correlation with CCND1 amplification and clinicopathological parameters. African Health Sciences, 19(2), 2140–2146. https://doi.org/10.4314/ahs.v19i2.
[15]Björklund, Å., Forkel, M., Picelli, S. et al. The heterogeneity of human CD127+ innate lymphoid cells revealed by single-cell RNA sequencing. Nat Immunol 17, 451–460 (2016). https://doi.org/10.1038/ni.3368
[16]Han, X., Wang, R., Zhou, Y., et al. (2018). Mapping the mouse cell atlas by microwell-seq. Cell, 172(5), 1091–1107.e17. https://doi.org/10.1016/j.cell.2018.02.001
[17]Zheng, G., Terry, J., Belgrader, P. et al. Massively parallel digital transcriptional profiling of single cells. Nat Commun 8, 14049 (2017). https://doi.org/10.1038/ncomms14049
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Aloy Chinwe Okechukwu (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
